• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Changes in expression levels of ERCC1, DPD, and VEGFA mRNA after first-line chemotherapy of metastatic colorectal cancer

Research Project

Project/Area Number 25670588
Research Category

Grant-in-Aid for Challenging Exploratory Research

Allocation TypeMulti-year Fund
Research Field Digestive surgery
Research InstitutionKumamoto University

Principal Investigator

BABA hideo  熊本大学, 大学院生命科学研究部, 教授 (20240905)

Co-Investigator(Kenkyū-buntansha) BABA Yoshifumi  熊本大学, 大学院生命科学研究部, 講師 (20599708)
Project Period (FY) 2013-04-01 – 2015-03-31
Project Status Completed (Fiscal Year 2014)
Budget Amount *help
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
KeywordsERCC1 / DPD / VEGFA / 大腸癌 / 化学療法 / バイオマーカー / 抗癌剤感受性 / 転移性肝腫瘍 / 大腸癌肝転移 / 抗癌剤感受性関連遺伝子 / 癌関連遺伝子 / LINE-1
Outline of Final Research Achievements

Our previous study showed that administering oxaliplatin as first-line chemotherapy increased expression levels of ERCC1and DPD in liver CRC metastases. Second, whether the anti-VEGF monoclonal antibody bevacizumab alters tumoral VEGFA levels is unknown. We conducted this study to validate our previous findings on ERCC1 and DPD, and clarifiy the response of tumoral VEGFA expression to bavacizumab administration. ERCC1 mRNA expression was significantly higher in the chemotherapy group than in the non-chemotherapy group, and were significantly correlated. VEGFA expression level was higher in patients receiving bevacizumab than in those who did not. This study confirmed that first-line oxaliplatin-based chemotherapy increases ERCC1 and DPD expression levels, potentially enhancing chemosensitivity to subsequent therapy. We also found that bevacizumab induces VEGFA expression in tumor cells, suggesting a biologic rationale for extending bevacizumab treatment beyond first progression.

Report

(3 results)
  • 2014 Annual Research Report   Final Research Report ( PDF )
  • 2013 Research-status Report
  • Research Products

    (9 results)

All 2014 2013 2012

All Journal Article (8 results) (of which Peer Reviewed: 8 results) Presentation (1 results)

  • [Journal Article] Statins inhibit tumor progression via an enhancer of zeste homolog 2-mediated epigenetic alteration in colorectal cancer.2014

    • Author(s)
      S. Ishikawa, H. Hayashi, K. Kinoshita, M. Abe, H. Kuroki, R. Tokunaga, S. Tomiyasu, H. Tanaka, H. Sugita, T. Arita, Y. Yagi, M. Watanabe, M. Hirotaand H. Baba
    • Journal Title

      Internationa Journal of Cancer

      Volume: Epub ahead of print Issue: 11 Pages: 2528-36

    • DOI

      10.1002/ijc.28672

    • Related Report
      2014 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Chemotherapy and targeted therapy for patients with initially unresectable colorectal liver metastases, focusing on conversion hepatectomy and long-term survival2014

    • Author(s)
      Beppu T, Miyamoto Y(equal contributor), Sakamoto Y, Imai K, Nitta H, Hayashi H, Chikamoto A, Watanabe M, Ishiko T, Baba H.
    • Journal Title

      Ann Surg Oncol

      Volume: 21 Suppl 3 Issue: S3 Pages: 405-13

    • DOI

      10.1245/s10434-014-3577-x

    • Related Report
      2014 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Efficacy of S-1 in colorectal cancer2014

    • Author(s)
      Miyamoto Y, Sakamoto Y, Yoshida N, Baba H
    • Journal Title

      Expert Opin Pharmacother

      Volume: 15 Issue: 12 Pages: 1761-70

    • DOI

      10.1517/14656566.2014.937706

    • Related Report
      2014 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Evaluation of the necessity of primary tumor resection for synchronous metastatic colorectal cancer.2014

    • Author(s)
      Miyamoto Y, Watanabe M, Sakamoto Y, Shigaki H, Murata A, Sugihara H, Etoh K, Ishimoto T, Iwatsuki M, Baba Y, Iwagami S, Yoshida N, Baba H.
    • Journal Title

      Surgery Today

      Volume: Epub ahead of print

    • Related Report
      2013 Research-status Report
    • Peer Reviewed
  • [Journal Article] Clinical implications of the LINE-1 methylation levels in patients with gastrointestinal cancer.2014

    • Author(s)
      Baba Y, Murata A, Watanabe M, Baba H.
    • Journal Title

      Surgery Today

      Volume: Epub ahead of print

    • Related Report
      2013 Research-status Report
    • Peer Reviewed
  • [Journal Article] Clinical implications of the LINE-1 methylation levels in patients with gastrointestinal cancer2013

    • Author(s)
      Baba Y, Murata A, Watanabe M, Baba H
    • Journal Title

      Surg Today

      Volume: (Epub ahead of print) Issue: 10 Pages: 1807-1816

    • DOI

      10.1007/s00595-013-0763-6

    • Related Report
      2014 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Methylation levels of LINE-1 in primary lesion and matched metastatic lesions of colorectal cancer.2013

    • Author(s)
      Murata A, Baba Y, Watanabe M, Shigaki H, Miyake K, Ishimoto T, Iwatsuki M, Iwagami S, Sakamoto Y, Miyamoto Y, Yoshida N, Nosho K, Baba H.
    • Journal Title

      Br J Cancer.

      Volume: 109 Issue: 2 Pages: 408-415

    • DOI

      10.1038/bjc.2013.289

    • Related Report
      2013 Research-status Report
    • Peer Reviewed
  • [Journal Article] CD44v6 expression is related to mesenchymal phenotype and poor prognosis in patients with colorectal cancer.2012

    • Author(s)
      Saito S, Miyamoto Y, et al.
    • Journal Title

      Oncol Rep.

      Volume: 29 Issue: 4 Pages: 1570-8

    • DOI

      10.3892/or.2013.2273

    • Related Report
      2013 Research-status Report
    • Peer Reviewed
  • [Presentation] 大腸癌におけるERCC1 isoformの発現レベル2014

    • Author(s)
      原田和人
    • Organizer
      第73回日本癌学会学術集会
    • Place of Presentation
      横浜
    • Year and Date
      2014-09-25 – 2014-09-27
    • Related Report
      2014 Annual Research Report

URL: 

Published: 2014-07-25   Modified: 2019-07-29  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi